Reference : A Comparative Study of the Antimycotic Activity of a Miconazole Hp-Beta Cyclodextrin ...
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/18760
A Comparative Study of the Antimycotic Activity of a Miconazole Hp-Beta Cyclodextrin Solution and a Surfactant Solution
English
Piel, Géraldine mailto [Université de Liège - ULg > Département de pharmacie > Pharmacie galénique et magistrale >]
Hayette, Marie-Pierre mailto [Université de Liège - ULg > > Microbiologie médicale >]
Evrard, Brigitte mailto [Université de Liège - ULg > Département de pharmacie > Pharmacie galénique >]
Van Hees, Thierry mailto [Université de Liège - ULg > Département de pharmacie > Pharmacie clinique et pharmacie hospitalière >]
De Mol, Patrick mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Microbiologie médicale et virologie médicale]
Delattre, Luc mailto [Université de Liège - ULg > Département de pharmacie > Département de pharmacie >]
1999
Journal de Pharmacie de Belgique
54
3, May-Jun
87-8
No
International
0047-2166
Forum des Sciences Pharmaceutiques
Société Belge des Sciences Pharmaceutiques
Spa
Belgique
[en] The antimycotic activity of a new parenteral solution containing miconazole was compared to that of a marketed solution (Daktarin IV solution). This solution has been withdrawn from the belgian market probably because of the toxic effects related to the presence of polyoxyl 35 castor oil. We propose a new formulation containing 10 mg of miconazole per ml (as the marketed solution), in combination with HP-beta cyclodextrin and lactic acid. The MIC of these two solutions were determined by broth microdilution method (following the NCCLS guidelines) against 15 yeasts and 16 filamentous fungi isolates. This study showed that MIC obtained with these two solutions are not significantly different. In vitro, the cyclodextrin solution has the same antimycotic activity as the Daktarin IV solution and can be proposed as a safe and effective parenteral solution to replace the previous surfactant solution.
Researchers ; Professionals
http://hdl.handle.net/2268/18760

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.